Could run nicelyIAN has come down significantly but the story got stronger. The sector sell off was wide spread, and now we are starting to see names recover. IAN should be one of the first movers, and glad it is, but also think we are seeing some curalife money come in, as that story will trade sideways likely with a few class action noise today. A lot to do about nothing but non the less, investors can pick up IAN for a ride. There are price targets at $14.